Genome-scale long noncoding RNA expression pattern in squamous cell lung cancer

Ying Wang1,2,*, Chen-Yue Qian1,*, Xiang-Ping Li3, Yu Zhang4, Hui He5, Jing Wang2, Juan Chen1, Jia-Jia Cui1, Rong Liu2, Hui Zhou2, Lin Xiao2, Xiao-Jing Xu4, Yi Zheng5, Yi-Lan Fu1,2, Zi-Yu Chen1,2, Xiang Chen1, Wei Zhang1, Cheng-Cheng Ye1, Hong-Hao Zhou2, Ji-Ye Yin5 & Zhao-Qian Liu1

In this study, we aimed to explore the long noncoding RNA expression pattern in squamous cell lung cancer (SQCC) on a genome-wide scale. Total RNAs were extracted from 16 lung SQCC patients’ normal and matched lung cancer tissues by Trizol reagent. The expression level of genome-wide scale lncRNA and mRNA was determined by microarray. qRT-PCR was used to validate the lncRNA expression level in 47 patients. Data analyses were performed using R and Bioconductor. A total of 2,748 up and 852 down regulated probes were identified to be significantly and differentially expressed in tumor tissues. The annotation result of their co-expressed mRNAs showed that the most significantly related category of GO analysis was development and differentiation, while the most significantly related pathway was cell cycle. Subgroup analysis identified that 46 and 18 probes were specifically differentially expressed in smoking and moderately differentiated tumors, respectively. Our study indicated that clusters of lncRNAs were significantly and differentially expressed in SQCC compared with normal tissues in the same subject. They may exert a significant role in lung cancer development and could be potential targets for future treatment of SQCC.

Lung cancer is the leading cause of cancer related death globally1. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the two main forms, among newly diagnosed patients, approximately 85% are NSCLC2. Squamous cell carcinoma (SQCC) is one of the most common histological subtypes of NSCLC, and account for approximately 30% of all cases3. Although a large number of studies were conducted, the causes of lung cancer still remain unknown. It is now widely accepted that lung cancer is multifactorial and both genetic and environmental factors play pivotal roles in its occurrence.

Long non-coding RNAs (lncRNAs) are noncoding RNAs with more than 200 nucleotide in length4. Although without protein coding capability, lncRNAs play an important role in a number of biological processes, including tumor suppressors modulation, RNA-RNA interactions, epigenetic and post-transcription regulation5. It is also reported that lncRNAs played a role in carcinogenesis and could be diagnostic or prognostic biomarkers for lung cancer5. For example, metastasis-associated lung adeno-carcinoma transcript 1 (MALAT1) was firstly identified in NSCLC and its expression was highly associated with NSCLC susceptibility, prognosis and metastasis6. Another IncRNA Hox transcript antisense intergenic RNA (HOTAIR) was also widely investigated, its expression was reported to be important in NSCLC development, prognosis and clinical relapse7,8. Some other reported NSCLC related IncRNAs includes growth arrest-specific transcript 5 (GAS5)9, Sox2 overlapping transcript (Sox2ot)10 and BRAF
activated non-coding RNA (BANCR)\textsuperscript{11} \textit{et al.} However, the knowledge of genome scale expression of lncRNAs and their potential biological function in SQCC is still lacking.

In the present study, we investigated the expression of lncRNAs in 16 squamous cell lung carcinoma tumors and matched adjacent non-tumor lung tissues (NTL) by microarray analysis. The results were further validated by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) in another 31 paired tissues. Then, we identified lncRNAs that were significantly differentially expressed in lung SQCC tissues, and integrated mRNA expression data to predict the possible function of those lncRNAs. Finally, we conducted the subgroup according to patients' age, smoking status, differentiation, complication and TNM stages, as well as an overlap analysis with two previously published data.

Results

Patients' enrollment and lncRNA categorization. Our initial screening recruited a total of 262 patients' tumor and matched NTL tissues, among which, 184 were other histological types of lung cancer than SQCC. Thus 78 paired samples were subjected to RNA extraction, however, half of the patients' samples couldn't be processed to further study because of low quality. At last, 47 paired samples were remained. The lncRNA and mRNA expression profile of 16 lung SQCC tumors and matched NTL tissues were detected using microarray, and remained 31 paired tissues were used as validation set. The overview of sample selection and analysis was indicated in Figure S1.

In this study, we determined the expression of a total of 32,781 lncRNA probes. Based on Derrien \textit{et al.'s} categorization of lncRNAs in the GENCODE gene annotation\textsuperscript{12}, we classified all tested lncRNAs into 5 groups: antisense, intergenic, intronic, processed transcript and unknown. The classification criteria was based on the lncRNA location with respect to protein-coding genes, 3 of them were exemplified in Fig. 1A–C.

Identification of distinctive lncRNA expressions between lung SQCC tumors and matched NTL. The locus-by-locus lncRNA probes of tumors vs. NTL tissues were firstly analyzed. By the criteria of corrected \( p \)-value < 0.05 and absolute fold change > 2, we identified 2,748 up regulated and 852 down regulated probes that were significantly and differentially expressed in tumor tissues compared with NTL (Table S1, Fig. 1D). We also analyzed the distinctive lncRNAs based on their categorizations, the results were indicated in Fig. 1E. Although more than half of the lncRNAs (56.89\%) were not categorized, among the successfully annotated lncRNAs, more intergenic (19.11\%) and processed transcript (16.17\%) than antisense (5.25\%) and intronic (2.58\%) were differentially expressed. This pattern was also existed in the both up and down regulated lncRNAs (Figure S2), except that the processed transcript was more than intergenic in the down regulated lncRNAs.

Next, the two-dimensional (2D) hierarchical clustering of the 3600 lncRNAs was explored between lung SQCC tumors and NTL tissues (Fig. 1F). The separate clusters between tumors and NTL tissues indicated that these lncRNAs expression were substantially different between tumor and NTL tissues. We also constructed the heatmaps of these lncRNAs according to their categorizations. As indicated in Figure S3, separate clusters between tumors and NTL tissues were also observed for antisense, intronic, processed transcript and unknown lncRNAs. However, for intergenic lncRNAs, 7 NTL tissues were classified into the same cluster of tumor tissues.

Finally, to ensure that our results was not population and technical specific, we assessed the expression level of 6 lncRNAs using qRT-PCR in all 47 paired lung SQCC tumors and NTL tissues. These lncRNAs were randomly chosen from differentially expressed lncRNA transcripts. In consistent with microarray analysis, the results demonstrated that all the 6 lncRNAs were down-regulated in lung SQCC tissues vs. matched non-tumor tissues (Fig. 1G).

Identification of potentially functionally lncRNAs in lung SQCC. For these 3,600 differentially expressed lncRNA probes, the function of most of them remains unknown. Therefore, we predicted their potential function via the annotation of their co-expressed mRNAs. Firstly, the genome wide mRNA expression profile of these 16 lung SQCC and matched NTL tissues were detected. Also, the criteria of corrected \( p \)-value < 0.05 and absolute fold change > 2 were used to identify significantly and differentially expressed mRNAs. Among the 30,201 detected probes, a total of 5,253 probes were found to be significantly differentially expressed (Fig. 2A, Table S2). 2,593 probes were up regulated, and 2,660 probes were down regulated. These differentially expressed probes were used to generate a heatmap, as indicated in Fig. 2B, they were clearly segregated into tumor and NTL clusters. This result suggested that these mRNAs were substantially different between tumor and NTL tissues.

We next investigated the correlation of differentially expressed lncRNAs with each dysregulated mRNAs. In order to predict the potential function of lncRNAs, their coexpressed mRNAs were subjected to GO annotation. In terms of the biological processes, most of the significantly related categories pointed to development and differentiation (Fig. 3A). 6 of the top 10 categories of molecular function were related to protein binding (Fig. 3B). With regards to cellular components, plasma membrane played most important role, indicated by its appearance in 4 most enriched categories (Fig. 3C). Then, the ConsensusPathDB database was used to identify which gene networks were affected by the aberrantly expressed lncRNAs, the top 10 significant pathways were indicated in Fig. 3D. It is interesting to note...
Figure 1. Identification of lncRNAs expression differences between lung SQCC tumors and NTL. (A–C) Schematic diagram of three different categories of lncRNA. (A) Intergenic lncRNA, RP11-88I21.1 and RP11-59J16.1, located between protein coding genes of PLXNA1 and TPRA1. (B) Intronic lncRNA, ESRG, located in intron of protein coding gene CACNA2D3. (C) Antisense lncRNAs, CTD-2526J17.7 and CTD-2562J17.9, overlaps protein coding gene ARRB1 on the opposite strand. (D) Volcano plot of the differential lncRNA expression analysis. X-axis: log₂ fold change (median tumor-median NTL); Y-axis: −1 × log₁₀ (FDR p-value) for each probes; Vertical dotted lines: fold change ≥2 or ≤2; Horizontal dotted line: the significance cutoff (FDR p-value = 0.05). (E) Distribution of lncRNAs differentially expressed in the lung SQCC tissue. (F) Two-dimensional hierarchical clustering of the significant and differentially expressed lncRNA probes in all samples (16 tumor tissues in gray vs. 16 NTL tissues in black). Probes are in rows; samples are in columns. Both up-regulated and down-regulated lncRNAs can be seen in tumors compared with normal tissues. (G) The expression of 6 randomly selected differentially expressed lncRNAs were validated by quantitative real-time PCR in all 47 patients. * p < 0.05, **p < 0.001 compared with NTL tissues.
that top 3 pathways were all associated with cell cycle, suggesting that this pathway might be regulated by the aberrantly expressed lncRNAs in the NSCLC cancer tissues.

Previously, Guttman et al. indicated that some lncRNAs were transcriptionally regulated by transcription factors (TFs)\textsuperscript{13}, we thus further predicted the TFs that could regulate these lncRNAs. The lncRNAs with PCC $> 0.95$ were included in the analysis, as a result, a total of 35 lncRNAs were predicted to be regulated by 95 TFs. As indicated in Fig. 4, these lncRNAs were mostly regulated by 5 TFs: CdxA, AML-1a (RUNX1), GATA-2, GATA-1 and MZF1. We further did a literature search about these TFs, and found that AML-1a (RUNX1), GATA-2 and MZF1 were demonstrated to be correlated with lung cancer previously\textsuperscript{14–16}.

Subgroup and overlap analysis of lncRNA expressions. To further verify the correlation of various lncRNA expression and lung SQCC, we next conducted subgroup analysis. The patients were firstly grouped according to their sex (male and female), age ($< 60$ and $\geq 60$ years old), smoking status (smokers and non-smokers), differentiation (low and moderate), complication (with and without) and TNM stages (I/II and III). Then, the correlation study was performed for each paired subgroups in both tumor and control tissues. As indicated in Fig. 5 and S4, very similar lncRNA expression profiles were observed in all paired subgroups. To further identify differential expressed lncRNA probes, we next conducted a locus-by-locus differential lncRNA expression analysis for these paired subgroups in both tumor and control tissues. Based on the criteria of corrected $p$-value $< 0.05$ and absolute fold change $> 2$, the differentially expressed lncRNAs were only observed in different smoking status and differentiation patients. As indicated in Fig. 5A, B and Table S3, compared with non-smokers, smokers showed 23 down regulated and 23 up regulated probes in tumor tissues. While normal tissues showed no significantly expressed lncRNA between smokers and non-smokers, indicated that these lncRNAs were specifically correlated with smoking for cancers. It is interesting to note that most of the down regulated probes pointed to H19 (imprinted maternally expressed transcript), which was previously reported to be a tumor suppressor and its methylation status correlated with smoking\textsuperscript{17}. On the other hand, compared with poor differentiation subgroups, 18 differentially expressed lncRNAs probes were observed in moderately differentiated tumors. Also, normal tissues showed no significantly expressed lncRNA between different differentiation subgroups, suggesting that these lncRNAs were specifically associated with tumor tissue differentiation. All of the 18 lncRNA probes were down regulated, however, most of them were not annotated.

---

**Figure 2. Significantly differentially expressed mRNAs in lung SQCC.** (A) Volcano plot of the differential mRNA expression analysis. X-axis: log\textsubscript{2} fold change (median tumor-median NTL); Y-axis: $-1 \times \log\textsubscript{10}$ (FDR $p$-value) for each probes; Vertical dotted lines: fold change $\geq 2$ or $\leq 2$; Horizontal dotted line: the significance cutoff (FDR $p$-value $= 0.05$). (B) Two-dimensional hierarchical clustering of the significant and differentially expressed mRNA probes in all samples (16 tumor tissues in gray vs. 16 NTL tissues in black). Probes are in rows; samples are in columns.
Next, to identify potential lncRNA expression-based subclasses of the 16 tumors, we performed a hierarchical clustering analysis using the 3600 significantly deregulated lncRNA probes. As showed in Fig. 5C, two distinct clusters were indicated (14 vs. 2). To investigate the relationship between these two clusters and their clinical properties, we conducted the statistical analysis for sex, age, smoking status, differentiation, complication and TNM stage. However, no significant difference was observed between two clusters for these clinical characteristics.

To compare our study with other studies, we did a literature search in the GEO database, only 1 dataset (GSE56850) of lung cancer lncRNA expression was uploaded using the same microarray platform of ours. We thus did an overlap analysis between these two studies. It was noteworthy that GSE56850 dataset was conducted in the adenocarcinoma. As indicated in Fig. 5D, a total of 602 lncRNA probes were significantly differentially expressed in both studies, most of the probes were expressed at the same direction. However, 50 up regulated probes were down regulated in the GSE56850 dataset, and 16 down regulated probes were up regulated in GSE56850 dataset. This result indicated that some lncRNAs may play different roles in different pathological types of NSCLC. The detail information of these 602 probes was listed in Table S4.

Previously, TCGA generated a large number of RNA-seq data of lung SQCC compared with non-tumor tissues. To learn about the overlap between our microarray and TCGA RNA-seq results, we compared current study’s differentially expressed mRNAs and lncRNAs with their results. As showed in Fig. 6A and Table S5, TCGA data identified more differentially expressed mRNAs than ours, two studies owned an overlap of 2893 mRNAs, among which 98.34% probes were expressed at the same direction. Similar to this result, we also identified less significantly differentially expressed lncRNAs compared with TCGA data (Fig. 6B and Table S6). 180 lncRNAs were overlapped between two investigations, and only 5 lncRNAs had different expression direction. Taken together, these results suggested that TCGA RNA-seq experiment identified more differentially expressed mRNAs and lncRNAs than ours, however, two studies had high consistency for the overlapped probes.

Discussion

In the present study, we investigated the genome-wide expression profile of lncRNAs in 16 squamous cell lung carcinoma tumors and matched adjacent NTL by microarray. A total of 2,748 up and 852 down regulated probes were identified to be significantly and differentially expressed in tumor tissues.
The annotation result of their co-expressed mRNAs showed that the most significantly related category of GO analysis was development and differentiation, while the most correlated pathway were cell cycle. Co-expression network construct indicated that some of the mostly connected mRNAs and TFs were previously reported to be dysregulated in lung cancer, including SOX2, FOXF1, PTK2B, XRCC2, AML-1 a (RUNX1), GATA-2 and MZF1. Our next subgroup analysis identified that 46 and 18 probes were specifically differentially expressed in smoking and moderately differentiated tumors, respectively. Finally, we conducted an overlap analysis with another adenocarcinoma study and TCGA RNA-seq results.

LncRNAs were emerging as a novel class of gene regulators to the cancers5. The expression pattern of lncRNAs in some certain types of cancers was investigated, including NSCLC20. NSCLC includes two major pathological types: adenocarcinoma and SQCC. However, the genome-scale lncRNA expression profile of lung SQCC was yet to be explored. In this study, we identified 3600 lncRNA probes showing significant differential expression in lung SQCC tissues. They can substantially distinguish lung SQCC and NTL tissues. Some certain dysregulated lncRNAs that were found in our study were also reported in previous other investigations, which supported the result for each other. One of the previously reported up regulated lncRNA was Sox2ot. In our study, 17 probes were designed to detect this lncRNA and 12 of them were up regulated, the average increase fold was 5.98. It was also noteworthy that mRNA Sox2 was increased 11.77 fold in the tumor tissues. Furthermore, based on our co-expression analysis, Sox2 was correlated with 9 Sox2ot probes. Our result showed that Sox2ot may regulate Sox2, and vice versa. Some previous studies also explored this possibility, however, the detail mechanism still remains unknown10,21. Another two examples were HOTAIR and MEG3. HOTAIR was widely reported as an oncogene, its expression enhanced NSCLC cells aggressive behavior and related to lymphatic invasion and relapse in SCLC patients7,8. In agreement with these reports, our result also showed 2.35 fold increased expression of this lncRNA in SQCC tissues. MEG3 was reported as a tumor suppressor, its expression was decreased in NSCLC tumor tissues and associated with poor prognosis22. Our result also showed 2.71 fold decreasing of MEG3 in tumor tissues. However, most of the differentially expressed lncRNAs identified in this study were novel and need further study.

Figure 4. LncRNA-TFs network analysis. LncRNA-TFs network consist of 35 top correlated lncRNAs (PCC > 0.95) and 95 their regulating TFs, they were connected by 1566 edges.
Although some lncRNAs are identified to play key roles in many biological processes such as cell differentiation, immune responses and tumorigenesis, most of their functions are not well understood. One approach for the functional prediction of lncRNAs was construct coding-non-coding gene co-expression network. This method was also used to predict the function of significantly dysregulated lncRNAs in the current study. In the present study, some of the mostly connected mRNAs were already reported to be correlated with lung cancer, including SOX2, FOXF1, PTK2B and VHL. We thus proposed that their predicted regulating lncRNAs may be correlated with lung cancer carcinogenesis through regulating these genes. Another network constructed in the current study was lncRNA-TFs network, AML-1a.
RUNX1), GATA-2 and MZF1 were among the mostly correlated TFs. Previous investigation showed that they were correlated with lung cancer, however, the mechanisms were still unclear. We thus speculated that these TFs may participate in lung cancer carcinogenesis through regulating the lncRNAs predicted in this study. However, these two hypothesis needs to be further investigated.

In this study, we identified 46 and 18 significantly differentially expressed lncRNAs correlated with smoking and tumor differentiation, respectively. One of them was H19, which was strongly downregulated in smokers’ cancer tissues. This lncRNA was widely reported to be correlated with smoking, our result supported their investigations. Except for H19, most of the other lncRNAs were not reported previously. However, these lncRNAs may be helpful to understand lung SQCC differentiation, as well as and the role of smoking in the lung cancer carcinogenesis. By performing hierarchical clustering analysis on tumors, we identified two distinct clusters (cluster1 vs. cluster2: 14 vs. 2). However, we didn’t further explore the different lncRNAs expression profiles between these two clusters, because of the too small sample size of cluster 2. This investigation need to be performed in a larger sample size in the future study to see if subtypes could be discovered in the lung SQCC. We also compared the dysregulated lncRNA probes in our investigation to those in a previous study conducted in adenocarcinoma. Although some overlaps existed between two studies, attention should be paid to the lncRNAs that were differently expressed in two datasets. These subtype specific lncRNAs were specifically dysregulated in one dataset or dysregulated to opposite direction in both datasets. Based on our analysis, most of the significantly differentially expressed lncRNAs were subtype specific, indicating that they play different role in SQCC and adenocarcinoma of lung. The function of these lncRNAs awaits further studies.

To further explore the overlap between microarray and RNA-seq results, we compared our findings with TCGA lung SQCC data. The comparison suggested that RNA-seq identified more significantly differentially expressed probes (both mRNA and lncRNA) than our microarray assay. For the overlapped probes, two studies had high consistency with each other. This result is in consistent with previous other investigations, indicating that RNA-seq is a more sensitive and highly replicable assay compared with microarray.

Taken these together, we identified a panel of dysregulated lncRNAs that may be potential biomarkers and correlated with carcinogenesis of lung SQCC. They may be lung SQCC specific lncRNAs and thus indicate for potential changes to diagnosis or therapy. We are conducting in vitro functional studies for some of these lncRNAs to further explore their detail functions. In conclusion, this study lays a foundation for further diagnostic, therapeutic and functional research of lung SQCC lncRNAs.

Materials and Methods

Study samples. This project’s protocol was approved by the Ethics Committee of Xiangya School of Medicine, Central South University with registration number of CTXY-110008-3. All the patients were provided written informed consents in compliance with the code of ethics of the World Medical
Association (Declaration of Helsinki) at the time of surgery for the donation of their tissue for this research. We obtained the clinical research admission on the Chinese Clinical Trial Registry (http://www.chictr.org/cn/) and the registration number is ChiCTR-RCC-12002830. All of the tissues were histologically confirmed and enrolled between September 2011 and September 2013 at Xiangya Hospital of Central South University and Hunan Province Tumor Hospital (Changsha, Hunan, China). All fresh tissues were frozen in liquid nitrogen immediately after resection and stored in −80 °C until use. Their basic clinical characteristics including age, smoking status, histology, sex, differentiation, complication and TNM stage were collected (Table 1).

Array data production. The experiment was performed in the laboratory of CapitalBio Corporation (Beijing, China). In brief, total RNA was first extracted using Trizol reagent (Invitrogen, Carlsbad, California, USA) and then purified using the NucleoSpin® RNA clean-up Kit (Macherey-Nagel, Düren, Germany). Extracted RNA was quantified by using NanoDrop ND-1000 (Thermo Scientific, Wilmington, Delaware, USA) spectrophotometer and the integrity was evaluated by 1% formaldehyde denaturing gel electrophoresis. 1 g total RNA was used to synthesize double-stranded cDNAs by in vitro transcription. The cDNA was labeled by Cy3-dCTP or Cy5-dCTP (GE Healthcare, Piscataway, New Jersey, USA) and hybridized to the Human 4×180 K expression microarray (Agilent Technologies, Santa Clara, California, USA). The data was extracted by Agilent Feature Extraction (v10.7) and was summarized, normalized and quality controlled using GeneSpring GX program (v11.5).

qRT-PCR. qRT-PCR was used to validate the lncRNA expression level as described previously28,29. In brief, the total RNA was isolated using Trizol reagent (Invitrogen) and then reverse transcribed to cDNA using PrimeScript™ RT-PCR Kit (Takara, Dalian, China) in accordance to the manufacturer’s protocol. Real-time PCR was performed using SYBR® Premix DimerEraser™ (Perfect Real Time) (Takara, Dalian, China) in Roche LightCycler 480 II Real-Time PCR system (Roche Diagnostics Ltd., Rotkreuz, Switzerland). The threshold cycle value (Ct) of each product was determined and normalized against that of the internal control of GAPDH. The differences of lncRNAs expression level were compared by t test using SPSS 13.0 (SPSS Inc, Chicago, Illinois, USA). P<0.05 was considered as statistically significant.

Data analysis. All data analyses were performed using R (http://www.r-project.org/, version 2.15.3) and Bioconductor30.

Differential expression analysis. Differential expression analysis was assessed using t-test, and the p-values were corrected for False Discovery Rate (FDR) by Benjamini-Hochberg (BH) procedure. Statistical significance was defined as FDR p-value < 0.05. In addition, a two fold change of expression level between comparison of tumors and NTL was defined as significantly different lncRNAs or mRNAs. The heat map,

| Patient No. | Sex   | Age at Diagnosis | Smoking status (pack-years value) | Differentiation | Location       | Complication         | TNM stage |
|-------------|-------|------------------|-----------------------------------|-----------------|----------------|----------------------|-----------|
| 1           | Male  | 58               | 35                                | Moderately      | Right, upper   | Hypertension         | II A      |
| 2           | Male  | 59               | 40                                | Moderately      | Left, upper    | No                   | I B       |
| 3           | Male  | 48               | 60                                | Moderately      | Right, upper   | No                   | I I B     |
| 4           | Male  | 71               | 5                                 | Moderately      | Left, upper    | Coronary heart disease | I B     |
| 5           | Male  | 59               | No                                | Poorly          | Right, lower   | No                   | I I A     |
| 6           | Male  | 57               | 115                               | Moderately      | Left, lower    | Hypertension         | I I B     |
| 7           | Male  | 53               | 30                                | Poorly          | Right, lower   | Chronic bronchitis   | I I B     |
| 8           | Male  | 65               | 80                                | Moderately      | Left            | No                   | I I A     |
| 9           | Female| 47               | No                                | Poorly          | Left, lower    | No                   | I I A     |
| 10          | Male  | 64               | 5                                 | Moderately      | Right, upper   | No                   | I I B     |
| 11          | Male  | 57               | 30                                | Poorly          | Left, upper    | Osteoarthritis       | I B       |
| 12          | Male  | 50               | 30                                | Moderately      | Left, upper    | No                   | I I A     |
| 13          | Male  | 49               | 45                                | Poorly          | Left, lower    | No                   | I B       |
| 14          | Male  | 65               | 15                                | Moderately      | Right, upper   | Hypertension         | I I A     |
| 15          | Male  | 68               | 30                                | Moderately      | Right, upper   | No                   | I B       |
| 16          | Female| 44               | No                                | Poorly          | Left, lower    | Cholecystitis/Chronic hepatitis | I I A |

Table 1. Clinical and phenotypical characteristics of 16 lung SQCC patients.
lncRNA-probe pairs, we calculated the Pearson correlation coefficients (PCC) of each dysregulated lncRNA and mRNA. The PCC < −0.8 or >0.8 and corrected p-value < 0.05 was considered as statistically significant.

**Functional classification and pathway analyses.** The Gene Ontology (GO) and pathway analysis was conducted by ConsensusPathDB database (http://consensuspathdb.org/). The GO analysis was divided into molecular function, biological process and cellular component. Also, a corrected p-value < 0.05 was the threshold for statistically significant correlation.

**Co-expression network analysis and overlap analysis.** To identify the co-expression lncRNA-mRNA pairs, we performed the Pearson correlation coefficients (PCC) of each dysregulated lncRNA and mRNA probe. The PCC < −0.8 or >0.8 and corrected p-value < 0.05 was considered as statistically significant. In addition, we predicted the potential lncRNA regulating transcription factors (TFs) using TFSearch (http://www.cbrc.jp/research/db/TFSEARCH.html). The searching areas include 2 kb upstream and 500 bp downstream of each lncRNA gene loci. Finally, the lncRNA-mRNA and lncRNA-TFs network was drawn by Cytoscape (v3.1.1).

The overlap analyzed dataset of GSE56580 and TCGA were downloaded from gene expression omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/) and lncRNAAnor (http://lncrnatator.ewha.ac.kr/index.htm) respectively.

**References**

1. Jamal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69–90 (2011).
2. Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E. & Adjei, A. A. Non-small cell lung cancer: epidemiology, risk factors, treatment and survivorship. Mayo Clin Proc 83, 584–94 (2008).
3. Travis, W. D. Pathology of lung cancer. Clin Chest Med 32, 669–92 (2011).
4. Ponting, C. P. & Belgard, T. G. Transcribed dark matter: meaning or myth? Hum Mol Genet 19, R162–8 (2010).
5. Prensner, J. R. & Chinnaiyan, A. M. The emergence of lncRNAs in cancer biology. Cancer Discov 1, 391–407 (2011).
6. Gopichandran, T., Hammerle, M. & Diederichs, S. MALAT1—a paradigm for long noncoding RNA function in cancer. J Mol Med (Berl) 91, 791–801 (2013).
7. Nakagawa, T. et al. Large noncoding RNA HOTAIR enhances aggressive biological behavior and is associated with short disease-free survival in non-small cell lung cancer. Biochem Biophys Res Commun 436, 319–24 (2013).
8. Ono, H. et al. Long noncoding RNA HOTAIR is relevant to cellular proliferation, invasiveness, and clinical relapse in small-cell lung cancer. Cancer Med 3, 632–42 (2014).
9. Shi, X. et al. A critical role for the long non-coding RNA GASS in proliferation and apoptosis in non-small-cell lung cancer. Mol Carcinog doi:10.1002/mc.22120 (2013).
10. Hou, Z. et al. A long noncoding RNA Sox2ot regulates lung cancer cell proliferation and is a prognostic indicator of poor survival. Int J Biochem Cell Biol 53, 380–8 (2014).
11. Sun, M. et al. Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition. Mol Cancer 13, 68 (2014).
12. Derrien, T. et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 22, 1775–89 (2012).
13. Guttman, M. et al. Chromatin signature reveals a thousand highly conserved non-coding RNAs in mammals. Nature 458, 223–7 (2009).
14. Tsai, L. H. et al. The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss. Oncogene 34, 1641–9 (2015).
15. Huang, W. et al. Validation and target gene screening of hsa-miR-205 in lung squamous cell carcinoma. Chin Med J (Engl) 127, 272–8 (2014).
16. Eichhoff, B. et al. Trichostatin A modulates expression of p21waf1/cip1, Bcl-xl, ID1, ID2, ID3, CRAB2, GATA-2, hsp86 and TFIID/TAFII31 mRNA in human lung adenocarcinoma cells. Biol Chem 381, 107–12 (2000).
17. Chen, L. M., Nergard, J. C., Ni, L., Rosser, C. J. & Chai, K. X. Long-term exposure to cigarette smoke extract induces hypomethylation at the RUNX3 and IGF2-H19 loci in immortalized human uterine cells. PLoS One 8, e65513 (2013).
18. Zhao, X. et al. Expression profiles and initial confirmation of long noncoding RNAs in Chinese patients with pulmonary adenocarcinoma. Onco Targets Ther 7, 1195–204 (2014).
19. Cancer Genome Atlas Research, N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519–25 (2012).
20. Yang, J. et al. Analysis of lncRNA expression profiles in non-small cell lung cancers (NSCLC) and their clinical subtypes. Lung Cancer 85, 110–5 (2014).
21. Amaral, P. P. et al. Complex architecture and regulated expression of the Sox2ot locus during vertebrate development. RNA 15, 2013–27 (2009).
22. Lu, K. H. et al. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer 13, 461 (2013).
23. Mercer, T. R., Dinger, M. E. & Mattick, J. S. Long non-coding RNAs: insights into functions. Nat Rev Genet 10, 155–9 (2009).
24. Liao, Q. et al. Large-scale prediction of long non-coding RNA functions in a coding-non-coding gene co-expression network. Nucleic Acids Res 39, 3864–78 (2011).
25. Kaplan, R. et al. Monoallelic up-regulation of the imprinted H19 gene in airway epithelium of phenotypically normal cigarette smokers. Cancer Res 63, 1475–82 (2003).
26. Marioni, J. C., Mason, C. E., Mane, S. M., Stephens, M. & Gilad, Y. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res 18, 1509–17 (2008).
27. Bradford, J. R. et al. A comparison of massively parallel nucleotide sequencing with oligonucleotide microarrays for global transcription profiling. BMC Genomics 11, 282 (2010).
28. Yin, J. Y. et al. Translational regulation of RP2A via internal ribosomal entry site and by eIF3a. Carcinogenesis 34, 1224–31 (2013).
29. Huang, Q. et al. Two Novel Functional Single Nucleotide Polymorphisms of ADRB3 Are Associated With Type 2 Diabetes in the Chinese Population. J Clin Endocrinol Metab 98, E1272–7 (2013).
30. Gentleman, R. C. et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5, R80 (2004).
31. Park, C., Yu, N., Choi, L., Kim, W. & Lee, S. IncRNAtor: a comprehensive resource for functional investigation of long non-coding RNAs. *Bioinformatics* **30**, 2480–5 (2014).

**Acknowledgments**
We are grateful for all the contributions that supported this study. This work was supported in part by National High-tech R&D Program of China 863 Program Grant 2012AA02A517 (Z-Q. Liu), National Natural Science Foundation of China Grants 81173129 and 81373490 (Z-Q. Liu), and 81202595 (J-Y, Yin), Program for the Special Scientific Research Foundation of Doctor Disciplines in University of Ministry of Education of China Grant 20110162110034 (Z-Q. Liu), Hunan Provincial Natural Science Foundation of China Grant 12JJ7006 (Z-Q. Liu), and 2015JJ1024 (J-Y, Yin).

**Author Contributions**
Y.W., J.Y.Y. and Z.Q.L. conceived and designed the experiments, Y.W. and C.Y.Q. performed the experiments, Y.W., J.Y.Y. and R.L. analyzed the data, Y.W., X.P.L., J.J.C., J.W., H.H., C.Y.Q., Yu Z., C.C.Y., Y.L.F., Z.Y.C. and J.Y.Y. contributed clinical samples and data. Y.W. and J.Y.Y. wrote the manuscript. Y.W., X.J.X., J.Y.Y., X.C., L.X., H.Z., W.Z., Yu Z., Yi Z., Z.Q.L. and H.H.Z. edited the manuscript. All authors reviewed the manuscript.

**Additional Information**
*Supplementary information* accompanies this paper at http://www.nature.com/srep

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Wang, Y. et al. Genome-scale long noncoding RNA expression pattern in squamous cell lung cancer. *Sci. Rep.* **5**, 11671; doi: 10.1038/srep11671 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/